Piper Sandler raised the firm’s price target on Exelixis (EXEL) to $38 from $37 and keeps an Overweight rating on the shares. Following its FY24 preannouncement, Exelixis reported Q4 earnings with a total revenue of $567M and net cabo sales of $515M, the firm notes. Looking forward to 2025, guidance was reiterated across the board with cabo’s growth trajectory holding steady.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
- Exelixis price target raised to $45 from $38 at Citi
- Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib
- Exelixis Reports Strong 2024 Financial Results
- Exelixis: Buy Rating Backed by Strong Financial Performance, Promising Drug Pipeline, and Positive Risk/Reward Profile